Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?

Orbimed Advisors sold 281,408 shares on June 15, 2026, generating nearly $13 million at an average price of $45.02 per share. The report is primarily a factual disclosure of a large share sale by a medical-focused hedge fund, with limited evidence of a broader fundamental change. The signal is modestly negative for sentiment but unlikely to have a major standalone market impact.

Analysis

Orbimed Advisors sold 281,408 shares on June 15, 2026, generating nearly $13 million at an average price of $45.02 per share. The report is primarily a factual disclosure of a large share sale by a medical-focused hedge fund, with limited evidence of a broader fundamental change. The signal is modestly negative for sentiment but unlikely to have a major standalone market impact.